Canaccord analyst William Plovanic lowered the firm’s price target on Acutus Medical to $1.00 from $1.91 and keeps a Hold rating on the shares. The analyst said we believe the company will leverage its existing US customer base and leaner organization to drive increasing growth and decreasing operating losses and cash usage.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AFIB:
- Acutus Medical sees FY23 revenue $18M-$21M, consensus $20.46M
- Acutus Medical reports Q4 EPS (63c), consensus (71c)
- Acutus Medical Reports Fourth Quarter and Full Year 2022 Financial Results
- Acutus Medical management to meet virtually with BTIG
- Acutus Medical to Announce Fourth Quarter and Full Year 2022 Financial Results